Patients with moderate-to-severe atopic dermatitis (AD) were more likely to have clinically meaningful responses when treated with dupilumab at doses of 300 mg either weekly or every 2 weeks compared with those on placebo, according to a post hoc analysis of the phase III SOLO 1 and SOLO 2* trials presented as a poster at AAD 2019.
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.
Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.